ACELYRIN is a late-stage clinical biopharma company focused on the development of therapies targeting unmet medical needs in immunology, specifically through the advancement of izokibep and lonigutamab for conditions like non-infectious non-anterior uveitis and thyroid eye disease. By accelerating the clinical trials and commercialization processes, ACELYRIN aims to deliver transformative treatments that improve patient outcomes and quality of life.
Funding
$300M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ABFounders
Product
Problem
Many immune-mediated diseases lack targeted therapies, forcing patients to cycle through treatments with limited efficacy and significant side effects. Current treatments often rely on broad immunosuppression, failing to address the specific drivers of immune dysfunction. This can lead to suboptimal clinical outcomes and a reduced quality of life for patients.
Solution
ACELYRIN is a biopharmaceutical company focused on developing targeted, oral therapies for immune-mediated diseases. Their precision approach aims to replace broad immunosuppression by focusing on key drivers of immune dysfunction. By leveraging genetic and translational insights, ACELYRIN develops next-generation treatments designed to achieve improved clinical outcomes for patients. Their lead candidate, ESK-001, is a highly selective, next-generation oral TYK2 inhibitor currently in Phase 3 clinical trials for moderate-to-severe plaque psoriasis.
Target Audience
The primary target audience includes patients suffering from immune-mediated diseases such as moderate-to-severe plaque psoriasis, and the healthcare professionals who treat them.
Features
- ESK-001: A highly selective, next-generation oral TYK2 inhibitor
- Precision approach targeting specific drivers of immune dysfunction
- Oral therapies designed for improved patient convenience and adherence
- Clinical programs focused on immune-mediated diseases with unmet needs
- Development pipeline of novel drug candidates